Patent classifications
A61K39/02
Methods of producing bioconjugates of <i>E. coli </i>o-antigen polysaccharides, compositions thereof, and methods of use thereof
Methods of producing bioconjugates of O-antigen polysaccharides covalently linked to a carrier protein using recombinant host cells are provided. The recombinant host cells used in the methods described herein encode a particular oligosaccharyl transferase enzyme depending on the O-antigen polysaccharide bioconjugate to be produced. The oligosaccharyl transferase enzymes can be PglB oligosaccharyl transferase or variants thereof. Also provided are compositions containing the bioconjugates, and methods of using the bioconjugates and compositions described herein to vaccinate a subject against extra-intestinal pathogenic E. coli. (ExPEC).
Antibodies for prevention, treatment and diagnosis of <i>P. gingivalis </i>infection
Disclosed are P. gingivalis antibodies raised against a chimeric or fusion protein, wherein the chimeric or fusion protein comprises a first peptide joined directly or through a linker to a second peptide or polypeptide, wherein (A) the first peptide comprises a region of a P. gingivalis trypsin-like enzyme and (B) the second peptide or polypeptide comprises an adhesin domain of P. gingivalis.
Methods, reagents and kits for detecting minimal residual disease
- Jacobus Johannes Maria Van Dongen ,
- José Alberto Orfao De Matos Correia E Vale ,
- Juan Alejandro Flores Montero ,
- Julia Maria Almeida Parra ,
- Vincent Henricus Johannes Van der Velden ,
- Sebastian Böttcher ,
- Anthonie Willem Langerak ,
- Ester Mejst{hacek over (r)}íková ,
- Tomasz Szczepański ,
- Matthias Ritgen ,
- Paulo Jorge Monteiro Da Silva Lucio
The invention relates to the field of minimal residual disease (MRD) diagnostics, which is progressively more applied for the evaluation of treatment effectiveness in patients with a hematological malignancy, such as B-cell precursor acute lymphoblastic leukemia (BCP-ALL), B-cell chronic lymphocytic leukemia (B-CLL), and multiple myeloma (MM). Provided are unique reagent compositions with carefully selected and thoroughly tested combinations of antibodies, for ≥8-color flow cytometric stainings as well as for 10-color and 12-color flow cyometric stainings, which can reach sensitivities of at least 10.sup.−4, even down to 10.sup.−5. Also provided are diagnostic kits and methods for detecting MRD.
Mutant fragments of OspA and methods and uses relating thereto
The present invention relates to compositions and methods for the prevention and treatment of Borrelia infection. Particularly, the present invention relates to a polypeptide comprising a hybrid C-terminal fragment of an outer surface protein A (OspA), a nucleic acid coding the same, an antibody specifically binding the same, a pharmaceutical composition (particularly for use as a medicament or in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid and/or the antibody, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
CANCER IMMUNOTHERAPY USING TRANSFUSIONS OF ALLOGENEIC, TUMOR-SPECIFIC CD4+ T CELLS
The invention provides methods and compositions for administration of allogeneic lymphocytes as an exogenous source of CD4+ T cell help for endogenous, tumor-reactive CD8+ T cells.
CELL SURFACE ANCHORING ANTIGEN CONJUGATES TO TREAT CANCER
This disclosure provides cancer cell lysing agent, formulations comprising cancer cell lysing agent, and methods of using the same for treating cancer.
MYCOPLASMA VACCINE COMPOSITION AND METHODS
Described are vaccine compositions, methods of manufacture thereof, and methods of treating or preventing certain bacterial infections in humans and other mammals. For example, described are compositions comprising bacterial cell extracts that have undergone pretreatment such that lipid moieties have been cleaved from bacterial lipoproteins, thereby forming a vaccine composition that can stimulate a desired mammalian immune response while avoiding unwanted negative effects.
MYCOPLASMA VACCINE COMPOSITION AND METHODS
Described are vaccine compositions, methods of manufacture thereof, and methods of treating or preventing certain bacterial infections in humans and other mammals. For example, described are compositions comprising bacterial cell extracts that have undergone pretreatment such that lipid moieties have been cleaved from bacterial lipoproteins, thereby forming a vaccine composition that can stimulate a desired mammalian immune response while avoiding unwanted negative effects.
T cell receptors and peptides derived by mutations for the treatment of cancer
The present invention relates to a method for providing a neopeptide-specific T cell, wherein the neopeptide-specific T cell forms a complex having a half-life (T½) of at least 50 s with a neopeptide-MHC monomer. The present invention further relates to a T cell obtainable by the method as well as a pharmaceutical composition comprising such T cells.
Immunogenic compositions
Technologies for the prevention and/or treatment of nosocomial infections.